FDA Designates Pracinostat Orphan Drug for AML
The FDA has granted Orphan Drug designation to Pracinostat for the treatment of acute myeloid leukemia.
Diagnosis & Disease Information
Single Mutation in Bone Cells May Initiate AML
Acute myeloid leukemia is a blood cancer but, for many patients, the cancer may originate from an unusual source: a mutation in their bone cells.
Coffee in Pregnancy Linked to Childhood Leukemia Risk
Maternal coffee consumption during pregnancy is associated with increased risk of childhood acute leukemia.
Novel STAT5 Targets FasL in AML
Experts discuss miR-590, a novel STAT5 oncogenic miRNA that targets FasL in AML.
Biomarkers, AlloHSCT Predict Post-AML Relapse Prognosis
Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.
New Assay Paves Way for ‘Personalized’ Therapy in AML
High-throughput sensitivity assay may make “personalized” therapy possible in relapsed or refractory AML.
Leukemia, B-cell Lymphoma Management Not Always Evidence Based
Clinical practices does not always reflect evidence-based expert opinion when it comes to management of acute or chronic myeloid leukemia (AML, CML) and B-cell lymphomas.
Gemtuzumab Ozogamicin Reduces Pediatric AML Relapse Risk
Adding gemtuzumab ozogamicin to standard therapy improved event-free survival improved in children with de novo acute myeloid leukemia.
Drug Could Improve Outcomes for Children with High-Risk Leukemia
Results from a new study could benefit some children with high-risk AML. A therapeutic regimen that combined the GO with conventional three-drug chemotherapy was associated with improved survival in children with AML who underwent bone marrow transplantation.
Volasertib Receives Breakthrough Therapy Designation for AML
The FDA has granted Breakthrough Therapy designation to volasertib (Boehringer Ingelheim) for the treatment of patients ≥65 years old with previously untreated acute myeloid leukemia (AML), ineligible for intensive remission induction therapy.
- Loading...
Loading...
Loading... 
Loading...